Medigene, Will-Pharma sales and marketing update

Medigene said Will-Pharma launched Veregen sinecatechins in the Netherlands to treat genital warts. In 2011, Will-Pharma received exclusive marketing rights to Veregen in Belgium, the Netherlands and Luxembourg to treat genital warts. Medigene is eligible for double-digit royalties and sales milestones (see BioCentury, March 14, 2011). ...